

Mothers, babies and friendly bacteria

Lynne M Beattie, Lawrence T Weaver

There have been a number of reports recently that mother's breast milk may be a source of beneficial bacteria that colonise her infant's gastrointestinal tract.¹⁻¹⁶ The human gut is the home of a large community of bacteria which plays a part in a range of activities which contribute to our health. Occupying the colon, where their collective number of cells exceeds that of their host by a factor of 10, the 'gut microbiota' enjoy an intimate and mutually beneficial relationship with the multicellular organism they inhabit. With metabolic activities as diverse and complex as those of the liver, they can be considered an organ in their own right.¹⁷ These 'friendly' bacteria are crucial for the maintenance of health at all stages of life, contributing to immune function and defence against infections, protecting against some cancers and digestive diseases, synthesising micro-nutrients and concluding the digestion of food components which escape assimilation in the small intestine.¹⁸

The microbiota of the gastrointestinal tract are acquired at birth and their rate, type and pattern of colonisation may have immediate and long-term positive effects on health. While it has been assumed that they are acquired chiefly during vaginal delivery from mother's lower bowel, new reports suggest that they may also have their origin inside her breast. Mother's milk supplies the newborn with a large number of non-nutritional bioactive substances which assist in adaptation of the fetus to extrauterine life,¹⁹ and account for the superiority of human milk over artificially synthesised alternatives. While it is plausible that certain 'probiotic' bacteria (defined as endogenous bacteria that confer health benefits to their host²⁰) are among them, certain criteria must be fulfilled before they can be added to the long list of maternally derived, milkborne substances that benefit the newborn.

Department of Child Health, University of Glasgow, Royal Hospital for Sick Children, Glasgow, UK

Correspondence to Dr Lynne M Beattie, Department of Child Health, University of Glasgow, Royal Hospital for Sick Children, Dalnair Street, Yorkhill, Glasgow G3 8SJ, UK; lynne_beattie@hotmail.com

MICROBIAL COLONISATION OF THE GASTROINTESTINAL TRACT

The fetal gastrointestinal tract is sterile, but is rapidly colonised once the amniotic membranes rupture, usually at birth.²¹ During vaginal delivery the newborn face and mouth pass across the mother's anus and the microflora of her birth canal and rectum invade the neonatal intestinal tract, rapidly passing cranio-caudally so that the large bowel is quickly populated by bacteria.²² Within 4 days of delivery, maternally derived faecal microorganisms can be detected in the newborn colon.²³ Aerobic species, such as *Streptococci* and *Escherichia coli* flourish initially, followed by anaerobes. Exclusively breastfed infants have a predominance of the lactic acid-producing bacteria *Lactobacillus* and *Bifidobacterium* in their faeces by day 7 after birth. These two genera account for more than 90% of the bacterial consortia in the colon of breastfed term infants.²⁴

Bifidobacteria and *Lactobacilli* confer health benefits in several ways. They produce antimicrobial compounds such as *acidophilus* and other bacteriocidins,²⁵ they compete with enteropathogens by selectively consuming available nutrients,²⁶ they reduce intestinal permeability by tightening epithelial cells junctions,²⁷ and they produce short chain fatty acids, such as acetate and butyrate by the fermentation of unabsorbed carbohydrate, which strengthen the intestinal barrier.²⁸ Both bacterial genera excite local and systemic immune responses, including the production of secretory immunoglobulin A (SIgA), the modulation of phagocytosis, and the stimulation of the anti-inflammatory cytokine cascade.^{29 30}

BACTERIA IN MOTHER'S MILK

Human milk is a vehicle for the transport of nutrients and other essential substances from mother to young. It is a complex emulsion of lipids, carbohydrates, proteins, vitamins, minerals, white cells and non-nutritional substances which supplies not only the nutrients and energy required for infant growth and development, but also factors which assist in

microbiological protection, the maturation and regulation of defence mechanisms including the immune system, and accelerate postnatal maturation of the digestive system.³¹ To make the journey from mammary gland to infant gastrointestinal tract these milkborne substances must exist in forms that preserve their integrity, stability and activity.³² The infant digestive system must, in its turn, be equipped with mechanisms and pathways to recognise, process, utilise, absorb or reject milkborne substances, and with defences against potentially harmful, invasive or antigenic substances, including bacteria.³³ Breast and gut act in concert as a single organ, comparable to the endometrium-placenta interface, to ensure the traffic of nutrients as well as non-nutritional substances, from mother to baby.

The hypothesis that that some bacterial species found in the gastrointestinal tract of infants derive from mother's breast and are transferred directly in her milk derives from two observations: that the colonic microbiota of exclusively breastfed infants differs from those exclusively formula fed (taking into account other factors such as mode of delivery, postnatal and gestational age)¹⁴; and that human milk contains a spectrum of 'commensal bacteria', which inhibit *Staphylococcus aureus*, a known causative agent of mastitis.⁵ Following the discovery of identical *Lactobacillus* species in breast milk and neonatal stool samples of mother-infant pairs¹⁰ the principal bacteria that have been studied are *Bifidobacterium breve*, *bifidum*, *longum* and *pseudocatenulatum*.¹⁵ Given that these lactic-acid producing bacteria are strict anaerobes and difficult to culture, determination of their genetic identity requires molecular techniques, including random amplification of polymorphic DNA, pyrosequencing and PCR methods related to the 16S rRNA gene. Studies of the potential probiotic functions of these bacteria suggest that they possess characteristics which not only confer benefit to the infant, but also facilitate their safe passage from maternal lactating breast to infant colon.¹¹

These novel studies provide evidence that the strictly anaerobic bacterial strains identified within breast milk are unlikely to be contaminants from the skin. Gestationally dependent hormonally induced changes in the mammary gland may be conducive to the development of an anaerobic environment and promote the growth of lactic-acid producing bacteria by creating a biofilm

within the ductule to which they adhere and thrive.¹⁰ Such a specialised environment favours *Bifidobacteria* and *Lactobacilli*, which may be destined to become the dominant bacterial genera found in the infant colon. These reports that human milk is a source of bacteria which come to reside in the infant gut raise the question of their significance to the health of the newborn.¹²

TESTING THE ASSERTION THAT MILKBORNE BACTERIA ARE BENEFICIAL TO THE BABY

To test the assertion that bacteria found in the lactating mammary gland are a source of a beneficial colonic microbiota in the suckling newborn, criteria comparable to Koch's postulates must be fulfilled (box 1, A). Peaker and Neville³⁴ proposed such postulates when they addressed the biological significance of trophic and other non-nutritional substances in mother's milk to the health of the newborn. They argued that if a substance in mother's milk is to be shown to play a part in neonatal development and have specific positive effects in the newborn then certain criteria must be met. While these criteria make sense for the evaluation of the potential biologic effects of milkborne macromolecules, such as SIgA³⁵ and epidermal growth factor,³⁶ they must be revised to echo Koch's postulates when used to test the potential health-promoting (as opposed to pathogenic) effects of microorganisms. Such criteria require demonstration of the true origin and viability of milkborne bacteria throughout the journey from maternal breast to infant colon, and their beneficial effects when they reach the infant colon (box 1, B).

These criteria do not exclude the possibility that components of microorganisms (living or dead), such as DNA or protein, may stimulate an immune reaction or in other ways promote a healthy response. Nor do the criteria rule out other potential routes of transfer of 'friendly' bacteria and/or their products, such as transplacental or transpulmonary.³⁷ If bacteria in mother's milk are to be shown to play a part in neonatal development and have specific positive effects in the newborn then precise criteria must be met against which the true significance of the novel reports that mother's milk is a source of probiotic bacteria which colonise and thrive in the newborn gastrointestinal tract can be judged.

Studies performed so far offer strong circumstantial evidence that mother's breast milk is a likely source of probiotic

Box 1 Criteria by which to test the pathogenic, biological or probiotic effects of bacteria and/or bioactive substances.

A: Koch's postulates: pathogenic effects of bacteria

1. The microorganism must be isolated from the diseased organism and grown in pure culture.
2. The cultured microorganism must cause disease when introduced into a healthy organism.
3. The microorganism must be re-isolated from the inoculated, diseased host and identified as identical to the original specific causative organism.

B: Peaker and Neville's postulates: bioactive effects of milk macromolecules

1. An effect in the offspring must be obtained in response to exposure to the substance in milk.
2. This effect must be abolished by removal of that substance from milk and the effect must be restored when it is returned.
3. The substance must be present and active in milk.
4. The substance must retain its biological activity in the offspring to the site where it is postulated to act.

C: Beattie and Weaver's postulates: probiotic effects of milkborne bacteria

1. Bacteria in the human lactating mammary gland must be identifiable in situ, demonstrated to be live and to belong to a genetically stable population identical to that found in the infant gastrointestinal tract.
2. These bacteria must be shown to be present in human milk, and survive the journey from maternal breast to infant gastrointestinal tract.
3. Such bacteria must be shown to thrive, reproduce and have a biological or health-promoting (probiotic) effect in the newborn which is not present if they are absent.

bacteria that come to reside in the infant's gastrointestinal tract. However, while criteria 1 and 2 appear to have been satisfied, published studies have not demonstrated positive health-promoting effects in the newborn or its digestive system of bacteria that derive from mother's breast alone (rather than from mother's gut) which are denied to those babies who do not receive them. Satisfaction of criterion 3 requires observations or experiments that are capable of distinguishing the separate origin and independent effects of milk borne and faecally derived bacteria (box 1, C).

BIOLOGY OF LACTATION

The evolutionary biology of lactation and the co-evolution of mammals and microbes offer some clues as to the potential biological importance of the milkborne transfer of probiotic bacteria. Mammals have co-existed with microorganisms for many millions of years and their gastrointestinal tracts provide a relatively stable and secure microenvironment for bacteria which have become adapted to this unique habitat.³⁸ The human stomach is colonised by *Helicobacter pylori* (the stomachs of many mammals harbour species of *Helicobacter*), which lives in

relative harmony with its host in most circumstances.³⁹ The abomasum (fore-stomach) of ruminants, for example, is a microbial fermentation chamber that converts plant cellulose into short chain fatty acids to the benefit of bacteria and host. Co-evolution of host and bacteria has come about through the selection of the genotypes of each, leading to mutual adaptation to life together.

Lactation is thought to have originated in small reptilian ancestors of primitive mammals (therapsids) as a modification of the secretions of skin glands that secreted antibacterial substances to protect the newborn from infection.^{40 41} Mammalian milk, which is rich in antibacterial, antiviral and other protective substances, may well have had a greater importance initially as a source of defence than of nutrition. During the diversification and radiation of mammals in the Cenozoic era, lactation has been adapted and preserved as the principal mode of feeding of the young.⁴² Indeed milk feeding is a defining characteristic of all mammals.

Mother and young share 50% genetic identity and therefore many genes in common which favour the health of both.⁴³ Mother supplies her fetus in utero with immunoglobulins (particularly IgG)

and other substances that confer protection against microbial and other antigens via the placenta, and after birth, through the entero-mammary immune system she targets specific SIgA directly to the microorganisms to which she and her baby are exposed.⁴⁴ Her breast milk is also the source of a huge portfolio of non-specific immuno-defensive, modulatory, anti-inflammatory and other protective factors.⁴⁵ The transfer to her infant of a population of 'friendly bacteria' adds to this health-promoting endowment. Perpetuation of the harmonious co-existence of mother and baby demands not just the transfer of genes, nutrients, protective and trophic substances, but also microbiota that are genetically identical, safe and of proven advantage.⁴⁶

Human milk induces a predominance of *Bifidobacteria* and *Lactobacilli* in the infant gut microbiota. Conversely the artificially fed baby, deprived of mother's milk, has fewer *Bifidobacteria* and *Lactobacilli* within its faecal microbiota, in spite of exposure to her lower gastrointestinal tract at delivery. To safeguard transfer and colonic colonisation of the infant, mother's lactating breast may be a special reservoir of these microorganisms, which have become uniquely adapted to live and travel in milk. Nature favours 'redundancy' (dual vital organs, long intestinal tract with reserve capacity, for instance) because it offers 'fail-safe' systems and multiple mechanisms to safeguard essential functions.⁴⁷ The abundance of defence factors in milk strengthens the battery of non-lactational immune and non-immune protective mechanisms that have evolved to guard against infection in infancy.⁴⁸ Whether this milkborne source of *Bifidobacteria* and *Lactobacilli* is a 'backup' to ensure the transfer of a beneficial microbiota from mother to young, or a 'relic' of a biological system that has become redundant through the availability of a more ready and abundant maternal faecal supply, is a question posed by these reports.

Acknowledgements The authors thank Christine Edwards, Douglas Morrison, Judith Simpson and Andrew Barclay for their contributions to the subject of this review, and John Puntis for his helpful comments.

Funding LMB is supported by the Yorkhill Children's Foundation and the University of Glasgow.

Competing interests LTW is a member of the Scientific Advisory Board on Baby Nutrition of Danone, and has been a paid consultant to Nutricia and SMA.

Provenance and peer review Not commissioned; externally peer reviewed.

Accepted 23 June 2010

REFERENCES

1. **Abrahamsson TR**, Sinkiewicz G, Jakobsson T, *et al*. Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life. *J Pediatr Gastroenterol Nutr* 2009;**49**:349–54.
2. **Alp G**, Aslim B. Relationship between the resistance to bile salts and low pH with exopolysaccharide (EPS) production of *Bifidobacterium* spp. isolated from infants feces and breast milk. *Anaerobe* 2010;**16**:101–5.
3. **Díaz-Ropero MP**, Martín R, Sierra S, *et al*. Two *Lactobacillus* strains, isolated from breast milk, differently modulate the immune response. *J Appl Microbiol* 2007;**102**:337–43.
4. **Gueimonde M**, Laitinen K, Salminen S, *et al*. Breast milk: a source of bifidobacteria for infant gut development and maturation? *Neonatology* 2007;**92**:64–6.
5. **Heikkilä MP**, Saris PE. Inhibition of *Staphylococcus aureus* by the commensal bacteria of human milk. *J Appl Microbiol* 2003;**95**:471–8.
6. **Jiménez E**, Fernández L, Maldonado A, *et al*. Oral administration of *Lactobacillus* strains isolated from breast milk as an alternative for the treatment of infectious mastitis during lactation. *Appl Environ Microbiol* 2008;**74**:4650–5.
7. **Lara-Villoslada F**, Sierra S, Díaz-Ropero MP, *et al*. Safety assessment of the human milk-isolated probiotic *Lactobacillus salivarius* CECT5713. *J Dairy Sci* 2007;**90**:3583–9.
8. **Lara-Villoslada F**, Sierra S, Díaz-Ropero MP, *et al*. Safety assessment of *Lactobacillus fermentum* CECT5716, a probiotic strain isolated from human milk. *J Dairy Res* 2009;**76**:216–21.
9. **Maldonado J**, Lara-Villoslada F, Sierra S, *et al*. Safety and tolerance of the human milk probiotic strain *Lactobacillus salivarius* CECT5713 in 6-month-old children. *Nutrition* 2009; (In Press).
10. **Martín R**, Langa S, Reviriego C, *et al*. Human milk is a source of lactic acid bacteria for the infant gut. *J Pediatr* 2003;**143**:754–8.
11. **Martín R**, Olivares M, Marín ML, *et al*. Probiotic potential of 3 *Lactobacilli* strains isolated from breast milk. *J Hum Lact* 2005;**21**:8–17; quiz 18–21, 41.
12. **Martín R**, Jiménez E, Olivares M, *et al*. *Lactobacillus salivarius* CECT 5713, a potential probiotic strain isolated from infant feces and breast milk of a mother-child pair. *Int J Food Microbiol* 2006;**112**:35–43.
13. **Martín R**, Heilig HG, Zoetendal EG, *et al*. Cultivation-independent assessment of the bacterial diversity of breast milk among healthy women. *Res Microbiol* 2007;**158**:31–7.
14. **Martín R**, Heilig GH, Zoetendal EG, *et al*. Diversity of the *Lactobacillus* group in breast milk and vagina of healthy women and potential role in the colonization of the infant gut. *J Appl Microbiol* 2007;**103**:2638–44.
15. **Martín R**, Jiménez E, Heilig H, *et al*. Isolation of bifidobacteria from breast milk and assessment of the bifidobacterial population by PCR-denaturing gradient gel electrophoresis and quantitative real-time PCR. *Appl Environ Microbiol* 2009;**75**:965–9.
16. **Olivares M**, Díaz-Ropero MP, Martín R, *et al*. Antimicrobial potential of four *Lactobacillus* strains isolated from breast milk. *J Appl Microbiol* 2006;**101**:72–9.
17. **Edwards CA**, Parrett AM. Intestinal flora during the first months of life: new perspectives. *Br J Nutr* 2002;**88**(Suppl 1):S11–18.
18. **Collins MD**, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. *Am J Clin Nutr* 1999;**69**:1052S–7S.
19. **Weaver LT**. Significance of bioactive substances in milk to the human neonate. *Livest Prod Sci* 1997;**50**:139–46.
20. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria, October 2001. Food and Agriculture Organization of the United Nations, World Health Organization. http://www.who.int/entity/foodsafety/publications/fs_management/en/probiotics.pdf (accessed 27 May 2010).
21. **Jiménez E**, Marín ML, Martín R, *et al*. Is meconium from healthy newborns actually sterile? *Res Microbiol* 2008;**159**:187–93.
22. **Blakey JL**, Lubitz L, Barnes GL, *et al*. Development of gut colonisation in pre-term neonates. *J Med Microbiol* 1982;**15**:519–29.
23. **Sakata H**, Yoshioka H, Fujita K. Development of the intestinal flora in very low birth weight infants compared to normal full-term newborns. *Eur J Pediatr* 1985;**144**:186–90.
24. **Harmsen HJ**, Wildeboer-Veloo AC, Raangs GC, *et al*. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. *J Pediatr Gastroenterol Nutr* 2000;**30**:61–7.
25. **Corr SC**, Li Y, Riedel CU, *et al*. Bacteriocin production as a mechanism for the antiinfective activity of *Lactobacillus salivarius* UCC118. *Proc Natl Acad Sci USA* 2007;**104**:7617–21.
26. **Servin AL**. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. *FEMS Microbiol Rev* 2004;**28**:405–40.
27. **Ewaschuk JB**, Diaz H, Meddings L, *et al*. Secreted bioactive factors from *Bifidobacterium infantis* enhance epithelial cell barrier function. *Am J Physiol Gastrointest Liver Physiol* 2008;**295**:G1025–34.
28. **Kleerebezem M**, Vaughan EE. Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity. *Annu Rev Microbiol* 2009;**63**:269–90.
29. **Mohan R**, Koenig C, Schildt J, *et al*. Effects of *Bifidobacterium lactis* Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. *J Clin Microbiol* 2006;**44**:4025–31.
30. **Sjögren YM**, Tomicic S, Lundberg A, *et al*. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. *Clin Exp Allergy* 2009;**39**:1842–51.
31. **Weaver JT**, Prentice A. *Nutrition in infancy*. In: Morgan JB, Dickerson WT, eds. *Nutrition in Early Life*. London: Wiley, 2003:205–32.
32. **Weaver LT**. Transenteric signalling: mammary messages or white noise? *Adv Exp Med Biol* 2009;**639**:81–95.
33. **Weaver LT**, Walker WA. *Uptake of macromolecules in the neonate*. In: Lebenthal E, ed. *Human Gastrointestinal Development*. New York: Raven Press, 1989:731–48.
34. **Peaker M**, Neville MC. Hormones in milk: chemical signals to the offspring? *J Endocrinol* 1991;**131**:1–3.
35. **Hanson LA**, Korotkova M, Lundin S, *et al*. The transfer of immunity from mother to child. *Ann NY Acad Sci* 2003;**987**:199–206.
36. **Weaver LT**, Walker WA. Epidermal growth factor and the developing human gut. *Gastroenterology* 1988;**94**:845–7.
37. **Satokari R**, Grönroos T, Laitinen K, *et al*. *Bifidobacterium* and *Lactobacillus* DNA in the human placenta. *Lett Appl Microbiol* 2009;**48**:8–12.
38. **Mackie RI**, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. *Am J Clin Nutr* 1999;**69**:1035S–45S.
39. **Atherton JC**, Blaser MJ. Coadaptation of *Helicobacter pylori* and humans: ancient history, modern implications. *J Clin Invest* 2009;**119**:2475–87.

Leading article

40. **Long CA.** The origin and evolution of the mammary glands. *Bioscience* 1969;**19**:519–23.
41. **Pond CM.** The significance of lactation in the evolution of mammals. *Evolution* 1977;**31**:177–99.
42. **Oftedal OT.** Milk composition, milk yield and energy output at peak lactation: a comparative review. *Symp Zool Soc Lond* 1984;**51**:33–85.
43. **Haig D.** Genetic conflicts in human pregnancy. *Q Rev Biol* 1993;**68**:495–532.
44. **Kleinman RE,** Walker WA. The enteromammary immune system: an important new concept in breast milk host defense. *Dig Dis Sci* 1979;**24**:876–82.
45. **Goldman AS,** Chheda S, Garofalo R. Evolution of immunologic functions of the mammary gland and the postnatal development of immunity. *Pediatr Res* 1998;**43**:155–62.
46. **Turnbaugh PJ,** Ley RE, Hamady M, *et al.* The human microbiome project. *Nature* 2007;**449**:804–10.
47. **Weaver LT,** Austin S, Cole TJ. Small intestinal length: a factor essential for gut adaptation. *Gut* 1991;**32**:1321–3.
48. **Kunz C,** Rudloff S, Baier W, *et al.* Oligosaccharides in human milk: structural, functional, and metabolic aspects. *Annu Rev Nutr* 2000;**20**:699–722.



Mothers, babies and friendly bacteria

Lynne M Beattie and Lawrence T Weaver

Arch Dis Child published online August 24, 2010
doi: 10.1136/adc.2010.189639

Updated information and services can be found at:
<http://adc.bmj.com/content/early/2010/08/24/adc.2010.189639.full.html>

These include:

- | | |
|-------------------------------|--|
| References | This article cites 43 articles, 9 of which can be accessed free at:
http://adc.bmj.com/content/early/2010/08/24/adc.2010.189639.full.html#ref-list-1 |
| P<P | Published online August 24, 2010 in advance of the print journal. |
| Email alerting service | Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article. |

Notes

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>